We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals
AMPH

45 hedge funds and large institutions have $84.4M invested in Amphastar Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2,709% more capital invested

Capital invested by funds: $3M → $84.4M (+$81.4M)

2,150% more funds holding

Funds holding: 2 → 45 (+43)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
45
Holders Change
+43
Holders Change %
+2,150%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
43
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$20.6M
2
DM
Deerfield Management
New York
+$14.7M
3
JP Morgan Chase
JP Morgan Chase
New York
+$7.81M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$6.88M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$5.98M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$10.7K
2
KCM
Kennedy Capital Management
Missouri
-$1.02K

AMPH Hedge Fund Activity: Q3 2014 in Review

45 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2014, worth a combined $84.4M — up 2,709% from $3M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AMPH positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $20.6M. The largest seller was Alyeska Investment Group, cutting an estimated $10.7K.

  • 45 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2014, up from 2 in Q2 2014.
  • Funds reported $84.4M of Amphastar Pharmaceuticals stock for Q3 2014, up 2,709% quarter-over-quarter.
  • 43 funds opened new Amphastar Pharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +43 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q3 2014 was Broadfin Capital, an estimated $20.6M added.
  • The largest Amphastar Pharmaceuticals seller in Q3 2014 was Alyeska Investment Group, an estimated $10.7K sold.

Based on aggregated 13F filings for Q3 2014.